

DEPARTMENT OF HEALTH & HUMAN SERVICES

Office for Human Research Protections The Tower Building 1101 Wootton Parkway, Suite 200 Rockville, Maryland 20852

> Telephone: 301-435-8072 FAX: 301-402-2071 email: kborror@osophs.dhhs.gov

July 24, 2002

Jianhua Li, M.D. Deputy Director, Professor of Psychiatry Yunnan Institute for Drug Abuse Xi-Hua-Yuan, Kunming 650228 Yunnan Province, China

RE: Human Research Subject Protections Under Federalwide Assurance FWA-2238

<u>Research Project</u>: Molecular Genetics of Heroin Dependence <u>Principal Investigator</u>: Dr. Ming T. Tsuang <u>HHS Project Number</u>: R01 DA12846

Dear Dr. Jianhua Li:

The Office for Human Research Protections (OHRP) has reviewed your May 4, 2002 report regarding the above referenced research conducted at the Yunnan Institute for Drug Abuse (YIDA) that was submitted in response to OHRP's March 28, 2002 letter.

In its March 28, 2002 letter, OHRP expressed concern that the informed consent document approved by the YIDA Institutional Review Board (IRB) stated a different volume of blood drawn than the protocol indicated. OHRP acknowledges that, for technical reasons, the investigators obtained less blood than was originally called for in the protocol and the informed consent document. The informed consent document then was revised and approved by the YIDA IRB, and the subjects already consented were reconsented.

As a result, there should be no need for further involvement of OHRP in this matter. Of course, OHRP must be notified should new information be identified which might alter this determination.

Page 2 of 2 Jianhua Li, M.D.– YIDA July 24, 2002

OHRP appreciates the continued commitment of your institution to the protection of human research subjects. Please do not hesitate to contact me should you have any questions.

Sincerely,

Kristina C. Borror, Ph.D. Compliance Oversight Coordinator Division of Compliance Oversight

cc: Dr. Ming T. Tsuang, MMHC Lester Grinspoon, MMHC Dr. Ramon Greenberg, IRB Chair, MMHC Mr. Ma Kejian, IRB Chair, YIDA Commissioner, FDA Dr. David Lepay, FDA Dr. David Lepay, FDA Dr. Melody H. Lin, OHRP Dr. Michael A. Carome, OHRP Mr. George Gasparis, OHRP Ms. Yvonne Higgins, OHRP Mr Barry Bowman, OHRP